Local vancomycin powder delays, but does not prevent, hip and knee prosthetic infections
Background
Periprosthetic joint infection (PJI) remains a severe and debilitating complication following total hip arthroplasty (THA) and total knee arthroplasty (TKA). Despite advancements in surgical techniques and systemic antibiotic prophylaxis, PJI continues to pose significant challenges, often requiring complex revision surgeries and prolonged antibiotic regimens. The intraarticular application of vancomycin powder has emerged as a potential adjunctive strategy for PJI prevention, aiming to deliver high local antibiotic concentrations directly to the surgical site. However, its actual efficacy in reducing infection incidence and its safety profile, particularly regarding wound complications, remain subjects of ongoing debate among orthopedic surgeons.
Study Design
This retrospective monocentric cohort study analyzed 1,499 patients undergoing primary THA and TKA between January 1, 2022, and December 31, 2023. Patients were divided into two groups: a vancomycin group (VG, n=818) who received intraarticular vancomycin powder as part of their standard perioperative protocol from January 1, 2023, and a control group (CG, n=681) who did not. Researchers compared PJI rates, postoperative surgery-related complications (including wound healing disorders), and the time to infection onset between the two cohorts. Data was collected from patient records and analyzed for statistical significance.
Results
No statistically significant differences were observed between the vancomycin and control groups for overall PJI rates (1.0% in VG vs. 0.9% in CG, p=0.846), indicating no reduction in infection incidence. Similarly, the incidence of wound healing disorders did not differ significantly between groups (p=0.775). However, a notable finding was the statistically significant delay in the onset of infection in the vancomycin group compared to the control group. The median time to infection was 41.5 days in the VG versus 16.5 days in the CG, a difference of 25 days (p=0.006).
Key Findings
- Intraarticular vancomycin powder did not significantly reduce overall PJI rates (1.0% VG vs. 0.9% CG, p=0.846).
- No significant difference in wound healing disorders was observed between groups (p=0.775).
- Local vancomycin significantly delayed the onset of PJI from 16.5 days (control) to 41.5 days (vancomycin group, p=0.006).
Why It Matters
This study suggests that local vancomycin application may complicate the diagnosis and management of PJI rather than preventing it. By delaying the clinical manifestation of infection, it could lead to a longer period before symptoms become apparent, potentially pushing the infection into a more advanced stage. This delay might limit the effectiveness of less invasive treatment options, such as debridement and implant retention, necessitating more aggressive and complex interventions like two-stage revisions. For clinicians, this implies a need for heightened vigilance and potentially different diagnostic approaches in patients who received local vancomycin, as the typical early signs of PJI might be masked or postponed. It challenges the current practice of using local vancomycin as a primary preventative measure.
vancomycin
pji
periprosthetic-joint-infection
arthroplasty
hip-replacement
knee-replacement